What is coming next for vitiligo treatment?
Research can bring hope and confusion at the same time. Use this guide to read changing treatment news without turning a study into a promise.
Last updated
Phase 2
Investigational zasocitinib
A Phase 2 study is recruiting people with nonsegmental vitiligo. Recruiting status can change.
Status checked
Evidence · 1 source
- ClinicalTrials.gov — Phase 2 vitiligo study is recruiting. Source dated or checked . Confidence: moderate.
Investigational GIA632
A Phase 2 study is recruiting people with nonsegmental vitiligo. Recruiting status can change.
Status checked
Evidence · 1 source
- ClinicalTrials.gov — Phase 2 vitiligo study is recruiting. Source dated or checked . Confidence: moderate.
Investigational LY4005130
A Phase 2 study is recruiting adults with nonsegmental vitiligo. Recruiting status can change.
Status checked
Evidence · 1 source
- ClinicalTrials.gov — Phase 2 vitiligo study is recruiting. Source dated or checked . Confidence: moderate.
Phase 3
Investigational povorcitinib
Incyte reported that its Phase 3 vitiligo studies met their main goal. The company plans regulatory applications in 2027. It has not been filed or approved for vitiligo.
Status checked
Evidence · 1 source
- Incyte — Phase 3 result and planned future regulatory applications. Source dated or checked . Confidence: moderate.
Scenesse (afamelanotide)
Being studied in an active Phase 3 trial with NB-UVB. The study is no longer recruiting. It is not approved for vitiligo.
Status checked
Evidence · 1 source
- ClinicalTrials.gov — Phase 3 study is active, not recruiting, and includes NB-UVB. Source dated or checked . Confidence: moderate.
Filed or under review
Rinvoq (upadacitinib)
Submitted to the FDA and EMA for nonsegmental vitiligo. Europe’s CHMP issued a positive opinion, not an approval. The US vitiligo indication remains under review.
Status checked
Evidence · 3 sources
- AbbVie — Submitted to the FDA and EMA for nonsegmental vitiligo. Source dated or checked . Confidence: moderate.
- European Medicines Agency — CHMP positive opinion; European Commission decision pending. Source dated or checked . Confidence: high.
- US Food and Drug Administration — Current US label does not include vitiligo. Source dated or checked . Confidence: high.
Approved for another condition — not vitiligo
Litfulo (ritlecitinib)
FDA-approved for severe alopecia areata, not vitiligo. A Phase 3 vitiligo study is completed and an extension study remains active. No vitiligo filing or approval was verified.
Status checked
Evidence · 3 sources
- US Food and Drug Administration — Current FDA approval is for severe alopecia areata, not vitiligo. Source dated or checked . Confidence: high.
- ClinicalTrials.gov — Vitiligo Phase 3 study status is completed. Source dated or checked . Confidence: moderate.
- ClinicalTrials.gov — Vitiligo extension study remains active. Source dated or checked . Confidence: moderate.
Approved for vitiligo
RECELL
An FDA-approved, in-office cell-harvesting device for repigmentation of stable vitiligo lesions. It is not right for everyone; ask a specialist.
Status checked
Evidence · 1 source
- US Food and Drug Administration — FDA approval includes repigmentation of stable vitiligo lesions. Source dated or checked . Confidence: high.
Read every headline as treatment news, not a cure promise
A pipeline medicine may become another treatment option. A trial result, filing, or approval would not promise permanent freedom from vitiligo.
That distinction does not make progress small. It keeps hope attached to what the source actually shows and leaves room to plan for follow-up, burden, and uncertainty.
Ask your care team Keep treatment, trial, and safety choices with the team that knows your health and goals.
What a pipeline status means for you
A status is a progress marker, not a forecast of whether a treatment will reach you.
Words such as early study, later study, filed, and approved describe different points in a long process. The source-linked tracker is the place for current drug names and status.
You do not need to put current care on hold because something newer may arrive later.
What you can do now
Separate the news you are following from the choice in front of you today.
- Check the date and original source before sharing a headline.
- Write down what interests you: how it is used, who was studied, access, or side effects.
- Use the live trial finder if taking part in research interests you.
- Keep treating, pause with a plan, or choose no active treatment for now.
Ask your care team Keep treatment, trial, and safety choices with the team that knows your health and goals.
How we handle changing news
Volatile facts belong in a dated record, not in timeless page copy.
Each tracker item should show when it was checked and link to the source. If a status cannot be confirmed, it does not appear as a current fact.
What to say to your doctor or care team
Use these words as written, or change them to fit what you need.
- I saw a treatment in the pipeline. Is anything about it relevant to my choices today?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Would joining a study change or interrupt my current plan?Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What option that is available now best matches my goal?Saving keeps this on your device and needs JavaScript, which is off in this browser.